Hans Wildiers

591 total citations · 1 hit paper
10 papers, 233 citations indexed

About

Hans Wildiers is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Hans Wildiers has authored 10 papers receiving a total of 233 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 3 papers in Cancer Research. Recurrent topics in Hans Wildiers's work include HER2/EGFR in Cancer Research (6 papers), Cancer Treatment and Pharmacology (5 papers) and Advanced Breast Cancer Therapies (4 papers). Hans Wildiers is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), Cancer Treatment and Pharmacology (5 papers) and Advanced Breast Cancer Therapies (4 papers). Hans Wildiers collaborates with scholars based in Belgium, France and Italy. Hans Wildiers's co-authors include Laura Biganzoli, Rebecca Dent, Jean‐Yves Pierga, Xichun Hu, Qingyuan Zhang, Carlos H. Barrios, William Jacot, Gargi Patel, Jun Ke and Joyce O’Shaughnessy and has published in prestigious journals such as New England Journal of Medicine, Clinical Cancer Research and European Journal of Cancer.

In The Last Decade

Hans Wildiers

7 papers receiving 232 citations

Hit Papers

Trastuzumab Deruxtecan after Endocrine Therapy in Metasta... 2024 2026 2025 2024 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
    2024 144 citations Aditya Bardia, Xichun Hu et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hans Wildiers Belgium 4 189 79 56 50 30 10 233
Tetsuhiro Yoshinami Japan 6 116 0.6× 53 0.7× 50 0.9× 18 0.4× 33 1.1× 48 174
Esther Mena Gonzalez United States 6 193 1.0× 81 1.0× 27 0.5× 166 3.3× 28 0.9× 9 313
J.M. Vannetzel France 7 112 0.6× 114 1.4× 54 1.0× 26 0.5× 26 0.9× 10 220
Hai‐Qiang Mai China 11 135 0.7× 87 1.1× 51 0.9× 58 1.2× 38 1.3× 23 293
Lukas Delasos United States 8 121 0.6× 157 2.0× 62 1.1× 23 0.5× 64 2.1× 20 230
CE Geyer United States 9 217 1.1× 71 0.9× 148 2.6× 74 1.5× 28 0.9× 23 262
Sonja Heibl Austria 7 103 0.5× 53 0.7× 60 1.1× 36 0.7× 25 0.8× 21 155
Coralia Bueno Spain 8 111 0.6× 78 1.0× 63 1.1× 18 0.4× 36 1.2× 22 170
T. Valdez United States 6 274 1.4× 153 1.9× 66 1.2× 79 1.6× 40 1.3× 17 326
HJ Burstein United States 8 188 1.0× 61 0.8× 84 1.5× 50 1.0× 51 1.7× 25 223

Countries citing papers authored by Hans Wildiers

Since Specialization
Citations

This map shows the geographic impact of Hans Wildiers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans Wildiers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans Wildiers more than expected).

Fields of papers citing papers by Hans Wildiers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans Wildiers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans Wildiers. The network helps show where Hans Wildiers may publish in the future.

Co-authorship network of co-authors of Hans Wildiers

This figure shows the co-authorship network connecting the top 25 collaborators of Hans Wildiers. A scholar is included among the top collaborators of Hans Wildiers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans Wildiers. Hans Wildiers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Saura, Cristina, Hans Wildiers, Giampaolo Bianchini, et al.. (2025). European experience of patients with HER2-positive advanced/metastatic breast cancer accessing trastuzumab deruxtecan through a named patient program: the EUROPA T-DXd study. Frontiers in Oncology. 15. 1650981–1650981.
2.
3.
Bardia, Aditya, Xichun Hu, Rebecca Dent, et al.. (2024). Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. New England Journal of Medicine. 391(22). 2110–2122. 144 indexed citations breakdown →
4.
Joensuu, Heikki, Judith Fraser, Hans Wildiers, et al.. (2024). Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer. JAMA Network Open. 7(8). e2429772–e2429772.
5.
Laenen, Annouschka, Machteld Keupers, Ines Nevelsteen, et al.. (2024). Expression patterns of H3K27me3 for differentiation of breast fibroadenomas and phyllodes tumors. Apmis. 133(1). e13485–e13485. 2 indexed citations
6.
Hatse, Sigrid, Asier Antoranz, Maxim De Schepper, et al.. (2024). Dissecting the immune infiltrate of primary luminal B‐like breast carcinomas in relation to age. The Journal of Pathology. 264(3). 344–356. 1 indexed citations
7.
Brain, Étienne, Philippe Caillet, Nienke A. de Glas, et al.. (2019). HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology. Journal of Geriatric Oncology. 10(6). 1003–1013. 24 indexed citations
8.
Wyngaert, Tim Van den, Chantal Doyen, Lionel Duck, et al.. (2013). Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors. Supportive Care in Cancer. 21(12). 3483–3490. 22 indexed citations
9.
10.
Wildiers, Hans, Christel Fontaine, Peter Vuylsteke, et al.. (2010). Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment. 123(2). 463–469. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tetsuhiro Yoshinami Breakdown of academic impact, for papers by Esther Mena Gonzalez Breakdown of academic impact, for papers by J.M. Vannetzel Breakdown of academic impact, for papers by Hai‐Qiang Mai Breakdown of academic impact, for papers by Lukas Delasos Breakdown of academic impact, for papers by CE Geyer Breakdown of academic impact, for papers by Sonja Heibl Breakdown of academic impact, for papers by Coralia Bueno Breakdown of academic impact, for papers by T. Valdez Breakdown of academic impact, for papers by HJ Burstein
Rankless by CCL
2026